Scientific Program
ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to be share knowledge and develop collaborations.
Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.
List of Confirmed Titles and Speakers
| Anastasia | Albanese-O’Neill | USA | General population screening – Successes and pitfalls |
| Grazia | Aleppo | USA | Automated multi-hormone delivery approach to manage postprandial glycemic excursion |
| Kamil | Armacky | UK | Together with Jazz Sethi: The benefits / disadvantages of social media in context of technology: The Diabfluencers |
| Lia | Bally | Switzerland | · The role of estradiol in energy and glucose-insulin homeostasis |
| · Perioperative closed-loop use during major surgery | |||
| Katharine | Barnard-Kelly | UK | · Spotlight-AQ – Harnessing AI to deliver the first step in the precision medicine pathway |
| · Human behaviors that lead to optimal uptake / reception of automation | |||
| Tadej | Battelino | Slovenia | Consensus on the use of CGM in individuals with type 2 diabetes |
| Roy | Beck | USA | Cost benefits of CGM use in type 2 diabetes |
| Riccardo | Bellazzi | Italy | Machine learning methods predicting diabetes complications |
| Natalie | Bellini | USA | Sex differences in diabetes management in the primary care setting |
| Katrien | Benhalima | Belgium | Use of the Medtronic 780G hybrid closed-loop system in type 1 diabetes pregnancy |
| Richard | Bergenstal | USA | Real world data on CGM in type 2 diabetes – Glucose control improvement |
| Cari | Berget | USA | Simplifying devices: Practical tips for the clinician working with AID |
| Barbara Murn | Berkopec | Slovenia | Periodic re-education for automated insulin delivery (AID) |
| Torben | Biester | Germany | 2024 ISPAD Guidelines chapter on insulin delivery: Automation now for a better future |
| Bruce | Bode | USA | Managing glucose in the hospital with CGM and AID |
| Stefan | Bornstein | Germany | New strategies for curative therapies for diabetes |
| Emanuele | Bosi | Italy | Screening of type 1 diabetes and celiac disease of the general pediatric population in Italy: Progress and preliminary results |
| Charlotte | Boughton | UK | Closed-loop from diagnosis – What have we learnt from longest-ever closed-loop study? |
| Nick | Cahm | UK | The power of the patient voice: The Libre saga |
| Giacomo | Cappon | Italy | Creating digital twins: Model-driven and AI methods – An introduction |
| Anders | Carlson | USA | · Time in tight glycemic range: Overview of the physiological data |
| · View, Counterview: Time in tight range should be the primary treatment goals and outcome measure in diabetes – View | |||
| Eda | Cengiz | USA | Leveraging technology to address gender differences in diabetes |
| Manoj | Chawla | India | Real-world data of CGM on GLP-1 usage |
| Pratik | Choudhary | UK | · Hypoglycemia and driving: Staying safe |
| · The individual impact of hypoglycemia on daily living: Lessons for personalization | |||
| Mark | Clements | USA | Remote patient health in pediatric diabetes care – Where are we today? |
| Rosa | Corcoy | Spain | Real world experience of hybrid closed-loop use during type 1 diabetes pregnancy: A Spanish perspective |
| Tali | Cukierman-Yaffe | Israel | Assessment of cognitive & physical health agility in the busy diabetes clinic – The why & the how |
| Colin | Dayan | UK | DEBATE: Adaptive trials in the Post-Teplizumab era: To placebo or not to placebo? Yes, we should continue with placebo |
| Christophe | De Block | Belgium | 90-minute aerobic exercise tests in people with type 1 diabetes using the 780G AID system. Examining timing of temporary target: The ACT-ONE study |
| Hans | DeVries | The Netherlands | Fully closed-loop – Bihormonal approaches |
| Klemen | Dovc | Slovenia | Planned versus spontaneous exercise in type 1 diabetes |
| Steven | Edelman | USA | DEBATE: Is there a real unmet need for continuous ketone monitoring? – CON |
| Dominic | Ehrmann | Germany | Objectively measured vs. subjective perceptions of glucose control: What is more important? |
| Laya | Ekhlaspour | USA | · Meal compositions and postprandial glycemic management in fully closed-loop systems |
| · NAP @ Home – First outpatient studies of Neural-net artificial pancreas | |||
| Anas | El Fathi | USA | · Digital twins, replay simulation, and decision support |
| · AI bolus calculator for people on multiple daily injections (MDI) | |||
| Juan | Espinoza | USA | Evidence and ideas from decision support systems on the user experience of automation |
| Chiara | Fabris | USA | · Glycemic excursion minimization (GEM): A lifestyle intervention for the management of type 2 diabetes |
| · Impact of sex on the control of type 2 diabetes | |||
| Rodolfo | Galindo | USA | Future of novel basal insulins |
| Satish | Garg | USA | · CGM use and effect on hospitalization and ER visits in type 2 diabetes |
| · Newer GLP analogs for treatment of obesity in type 1 diabetes | |||
| Samita | Garg | USA | Prevalence and rationale for new terminologies in NAFLD |
| Michal | Gillon-Keren | Israel | The role of nutrition management in people using automated insulin delivery systems |
| Francesco | Giorgino | Italy | Incretin-based therapies for the treatment of obesity-related diseases |
| Amit | Gupta | India | Intermittent use of CGM in type 2 diabetes |
| Michael | Haller | USA | · Inhaled insulin in pediatrics (INHALE-1 – Peds Study) |
| · Stages and monitoring in early type 1diabetes | |||
| Matthias | Hebrok | Germany | Optimizing stem cell derived beta cell function for transplantation |
| Tim | Heise | Germany | Oral and glucose-sensitive insulins: Will we ever have them? |
| Simon | Heller | UK | Is it possible to reserve awareness of hypoglycemia with AID technology? |
| Norbert | Hermanns | Germany | How to achieve a precision medicine approach using CGM and ecological momentary assessment |
| Julie | Heverly | USA | Time in tight glycemic range – A crucial goal or an unnecessary burden: PwD perspective |
| Irl | Hirsch | USA | · What’s new in pulmonary inhaled insulin? |
| · What are the appropriate glucose targets in the ICU? | |||
| · CGM-based intensification and de-intensification of therapy in type 2 diabetes | |||
| Korey | Hood | USA | Scoping out gaps in automation in the diabetes tech space |
| Roman | Hovorka | UK | How do I see the future of AID? |
| Sufyan | Hussain | UK | · How to use hybrid-closed-loop systems in complex outpatient clinical situations |
| · Fully closed-loop – Can people just do it? Insights from approaches using current commercial and open-source (DIY) HCL systems | |||
| Daria | Igudesman | USA | The role of nutrition in optimizing outcomes of GLP1/GIP |
| Peter | Jacobs | USA | AI-enabled meal detection and dosing in automated insulin delivery systems |
| Laura | Jacobsen | USA | DEBATE: Adaptive trials in the Post-Teplizumab era: To placebo or not to placebo? No, we should use only active (approved) control |
| Anna | Kahkoska | USA | · Use of technology to re-align treatment in individuals with type 2 diabetes in various living situations |
| · Use of CGM to improve the care of older insulin dependent individuals with cognitive / functional impairment | |||
| Partha | Kar | UK | The reality of the use of technology – Introduction |
| Karen | Kennedy | UK | With Eleanor Scott: Bringing science into lives: The Implementers |
| David | Kerr | USA | Time in tight glycemic range – A crucial goal or an unnecessary burden: Health inequalities perspective |
| Jothydev | Kesavadev | India | From insulin pumps to aid in India: Status of adoptability among people, physicians, and politicians |
| Tomasz | Klupa | Poland | Use of AID systems in order to improve the care of older individuals with type 1 diabetes & cognitive / functional impairment |
| Noriko | Kodani | Japan | PwD voices in designing new technology options for treating diabetes: The Diabetes Designer |
| Antje | Körner | Germany | A holistic approach to understanding childhood obesity |
| Primož | Kotnik | Slovenia | Therapy for monogenic obesity |
| Boris | Kovatchev | USA | · How digital twins can enhance clinical trials |
| · Machine learning – The key to fully automated closed-loop | |||
| Bernhard | Kulzer | Germany | AID, CSII & CGM: Real-world insights |
| Lori | Laffel | USA | · Is there ongoing need for telehealth? |
| · Use of GLP1 analogs in youth with type 1 diabetes for weight management in youth | |||
| · SGLT2i use in young people following approval by FDA and EMA in type 2 diabetes | |||
| Goos | Laverman | The Netherlands | Taking optimal advantage of diabetes technology: Potential role of a technical physician in your team |
| David | Maahs | USA | Remote patient monitoring, logistics and challenges for reimbursement |
| Julia | Mader | Austria | · Navigating the skies: Managing diabetes during air travel |
| · Trends of diabetes technology use in different European countries | |||
| Farid | Mahmud | Canada | Editorial perspectives and ISPAD type 2 diabetes chapter update |
| Marco | Marigliano | Italy | Cam APS Fx in very young children in Italy (2-year follow up) |
| Chantal | Mathieu | Belgium | · EDENT1FI: Towards general population screening in Europe |
| · Precision medicine in stage 2 type 1 diabetes | |||
| Jamie | Matu | UK | Advances in pharmacological interventions for pediatric and adolescent obesity – Current status and future prospects |
| Barbara | McGowan | UK | New horizons for treating obesity |
| Viswanathan | Mohan | India | Do different types of prediabetes require different types of prevention approaches? |
| Othmar | Moser | Germany | · The use of AID and exercise in type 1 diabetes: A position statement of the EASD and ISPAD |
| · Fully closed-loop: From announced to unannounced exercise | |||
| Clara | Mosquera-Lopez | USA | · AI analytics and CGM data science |
| · Using exercise data in combination of AI to help prevent nocturnal hypoglycemia | |||
| Marie | Mouler | Israel | Diabetes technology in competitive sports: The queen’s gambit |
| Medha | Munshi | USA | Use of technology to re-align treatment in individuals with type 1 diabetes in various living situations |
| Helen | Murphy | UK | The role of CamAPS FX in type 1 diabetes pregnancy |
| Joshua | Neumiller | USA | Triggers that indicate need for re-alignment in older adults with diabetes |
| Revital | Nimri | Israel | Decision support systems for healthcare providers and people with diabetes |
| Kirsten | Nørgaard | Denmark | · Can decision support for evaluating automated insulin delivery (AID) uploads assist clinicians? |
| · Status on Stenpool – An uploading program with access to all devices | |||
| Maria Cristina | Nostro | USA | Optimizing differentiation and engraftment of stem cell-derived islets for type 1 diabetes treatment |
| Tal | Oron | Israel | With Moshe Phillip: Update on ADIR (Antibody Detection Israeli Research) project |
| Naushira | Pandya | USA | Treatment of type 1 diabetes in long term care facilities |
| Rakesh | Parikh | India | Artificial intelligence (AI) in diabetes clinic: Expanding horizons |
| Ewan R | Pearson | UK | Heterogeneity of obesity and type 2 diabetes diabetes |
| John | Pemberton | UK | A paradigm shift: Using CGM to dose physical activity between meals to optimize time in range |
| Jeremy | Pettus | USA | View, Counterview: Time in tight range should be the primary treatment goals and outcome measure in diabetes – Counterview |
| Moshe | Phillip | Israel | With Tal Oron: Update on ADIR (Antibody Detection Israeli Research) project |
| Elizabeth | Pyatak | USA | Individual networks between glucose, mood, and daily functioning |
| Neesha | Ramchandani | USA | Giving your best shot: Focusing on safety, efficacy & comfort |
| Eric | Renard | France | · Fully closed-loop – Insulin only approaches |
| · Diabetes technology in different age groups | |||
| Michael | Rickels | USA | Different ways to detect unawareness |
| Michael | Riddell | Canada | Physical activity, technology and type 2 diabetes: Opportunities and challenges |
| Julio | Rosenstock | USA | · Should GLP-1 RAs be stopped prior to elective surgery? |
| · Triple agonist in type 2 diabetes | |||
| Donna H | Ryan | USA | Lessons from the SELECT trial: Rethinking the clinical applications for the GLP-1RA semaglutide |
| Victoria | Salem | UK | Biomaterials to aid beta cell replacement – Current and future perspectives |
| Andrea | Scaramuzza | Italy | Which are the best therapeutic strategies when exercising? Comparison among different AID systems |
| Desmond | Schatz | USA | Update on efforts to interdict type 1 diabetes |
| Eleanor | Scott | UK | With Karen Kennedy: Bringing science into lives: The Implementers |
| Jane Jeffrie | Seley | USA | Innovative models that support inpatient diabetes care & education |
| Jazz | Sethi | India | Together with Kamil Armacky: The benefits / disadvantages of social media in context of technology: The Diabfluencers |
| Viral | Shah | USA | Use of CGM in pre-type 2 diabetes |
| Anath | Shalev | USA | Novel type 1 diabetes therapies targeting endogenous islet cells |
| Shlomit | Shalitin | Israel | Prevalence of obesity in type 1 diabetes |
| Devorah | Shapiro | Israel | Growing bigger and independent – A structured educational program for patients aged 9 -12 who were diagnosed at a very young age |
| Jennifer | Sherr | USA | · Evidence and ideas from automated insulin delivery on the user experience of automation |
| · DEBATE: Is there a real unmet need for continuous ketone monitoring – PRO | |||
| Smadar | Shilo | Israel | Data-Driven approaches in endocrinology: From CGM to omics data |
| Galit | Shiovitch-Mantzuri | Israel | Follow-up of families with early detection of type 1 diabetes; The nurse perspective |
| Carmel | Smart | Australia | · Changing behaviors to manage weight in children and adolescents with type 1 diabetes |
| · Is carb counting enough? Optimizing mealtime insulin dosing | |||
| Darja | Šmigoc Schweiger | Slovenia | Sex differences in cardiovascular risk facture in youth with type 1 diabetes |
| Harald | Sourij | Austria | Exercise and long-acting insulins |
| Courtney | South | Canada | The impact of technology use on diabetes-related nutrition behaviors |
| Andrew F | Stewart | USA | Human beta cell regenerative drug therapy: A journey from impossible to possible |
| Jannet | Svensson | Denmark | Diabetes technology and sleep |
| Molly | Tanenbaum | USA | Time in tight glycemic range: A crucial goal or an unnecessary burden – Qualitative data perspective |
| Maria | Vasiloglou | Switzerland | Effectiveness of app-based interventions on diabetes and nutrition |
| Josep | Vehi | Spain | Applications of generative AI to diabetes |
| Deborah | Wake | UK | AI takes diabetes management beyond AID |
| Emma | Wilmot | UK | What do people with diabetes expect from diabetes technology? |
| Yariv | Yogev | Israel | How do you know that your pregnant woman with diabetes is well controlled? |